These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 30506321)

  • 1. Isocitrate dehydrogenase gene mutations and 2-hydroxyglutarate accumulation in esophageal squamous cell carcinoma.
    Miyake K; Baba Y; Ishimoto T; Hiyoshi Y; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Ogata Y; Nagayama M; Silsirivanit A; Kobayashi D; Araki N; Baba H
    Med Oncol; 2018 Nov; 36(1):11. PubMed ID: 30506321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reductive carboxylation and 2-hydroxyglutarate formation by wild-type IDH2 in breast carcinoma cells.
    Smolková K; Dvořák A; Zelenka J; Vítek L; Ježek P
    Int J Biochem Cell Biol; 2015 Aug; 65():125-33. PubMed ID: 26007236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization.
    Ward PS; Lu C; Cross JR; Abdel-Wahab O; Levine RL; Schwartz GK; Thompson CB
    J Biol Chem; 2013 Feb; 288(6):3804-15. PubMed ID: 23264629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.
    Jin G; Reitman ZJ; Spasojevic I; Batinic-Haberle I; Yang J; Schmidt-Kittler O; Bigner DD; Yan H
    PLoS One; 2011 Feb; 6(2):e16812. PubMed ID: 21326614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the d-2-hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma.
    Mohammad N; Wong D; Lum A; Lin J; Ho J; Lee CH; Yip S
    Histopathology; 2020 Apr; 76(5):722-730. PubMed ID: 31609487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives.
    Mondesir J; Willekens C; Touat M; de Botton S
    J Blood Med; 2016; 7():171-80. PubMed ID: 27621679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
    Ward PS; Patel J; Wise DR; Abdel-Wahab O; Bennett BD; Coller HA; Cross JR; Fantin VR; Hedvat CV; Perl AE; Rabinowitz JD; Carroll M; Su SM; Sharp KA; Levine RL; Thompson CB
    Cancer Cell; 2010 Mar; 17(3):225-34. PubMed ID: 20171147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.
    Ward PS; Cross JR; Lu C; Weigert O; Abel-Wahab O; Levine RL; Weinstock DM; Sharp KA; Thompson CB
    Oncogene; 2012 May; 31(19):2491-8. PubMed ID: 21996744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development.
    Lemonnier F; Cairns RA; Inoue S; Li WY; Dupuy A; Broutin S; Martin N; Fataccioli V; Pelletier R; Wakeham A; Snow BE; de Leval L; Pujals A; Haioun C; Paci A; Tobin ER; Narayanaswamy R; Yen K; Jin S; Gaulard P; Mak TW
    Proc Natl Acad Sci U S A; 2016 Dec; 113(52):15084-15089. PubMed ID: 27956631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IDH1 and IDH2 have critical roles in 2-hydroxyglutarate production in D-2-hydroxyglutarate dehydrogenase depleted cells.
    Matsunaga H; Futakuchi-Tsuchida A; Takahashi M; Ishikawa T; Tsuji M; Ando O
    Biochem Biophys Res Commun; 2012 Jul; 423(3):553-6. PubMed ID: 22683334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia.
    Brunner AM; Neuberg DS; Wander SA; Sadrzadeh H; Ballen KK; Amrein PC; Attar E; Hobbs GS; Chen YB; Perry A; Connolly C; Joseph C; Burke M; Ramos A; Galinsky I; Yen K; Yang H; Straley K; Agresta S; Adamia S; Borger DR; Iafrate A; Graubert TA; Stone RM; Fathi AT
    Cancer; 2019 Feb; 125(4):541-549. PubMed ID: 30422308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roles of the oncometabolite enantiomers of 2-hydroxyglutarate and their metabolism by diverse dehydrogenases.
    Garcia I; Cornely K; Peterson CN; Berkmen MB
    Essays Biochem; 2024 Oct; 68(2):161-171. PubMed ID: 38919140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
    Dang L; White DW; Gross S; Bennett BD; Bittinger MA; Driggers EM; Fantin VR; Jang HG; Jin S; Keenan MC; Marks KM; Prins RM; Ward PS; Yen KE; Liau LM; Rabinowitz JD; Cantley LC; Thompson CB; Vander Heiden MG; Su SM
    Nature; 2009 Dec; 462(7274):739-44. PubMed ID: 19935646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.
    Borger DR; Goyal L; Yau T; Poon RT; Ancukiewicz M; Deshpande V; Christiani DC; Liebman HM; Yang H; Kim H; Yen K; Faris JE; Iafrate AJ; Kwak EL; Clark JW; Allen JN; Blaszkowsky LS; Murphy JE; Saha SK; Hong TS; Wo JY; Ferrone CR; Tanabe KK; Bardeesy N; Straley KS; Agresta S; Schenkein DP; Ellisen LW; Ryan DP; Zhu AX
    Clin Cancer Res; 2014 Apr; 20(7):1884-90. PubMed ID: 24478380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ivosidenib to treat adult patients with relapsed or refractory acute myeloid leukemia.
    Pasquier F; Lecuit M; Broutin S; Saada S; Jeanson A; Penard-Lacronique V; de Botton S
    Drugs Today (Barc); 2020 Jan; 56(1):21-32. PubMed ID: 32055803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isocitrate Dehydrogenase Mutations in Cancer: Mechanisms of Transformation and Metabolic Liability.
    Gunn K; Losman JA
    Cold Spring Harb Perspect Med; 2024 May; 14(5):. PubMed ID: 38191174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxia Induces Production of L-2-Hydroxyglutarate.
    Intlekofer AM; Dematteo RG; Venneti S; Finley LW; Lu C; Judkins AR; Rustenburg AS; Grinaway PB; Chodera JD; Cross JR; Thompson CB
    Cell Metab; 2015 Aug; 22(2):304-11. PubMed ID: 26212717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-Hydroxyglutarate in Cancer Cells.
    Ježek P
    Antioxid Redox Signal; 2020 Nov; 33(13):903-926. PubMed ID: 31847543
    [No Abstract]   [Full Text] [Related]  

  • 19. Isocitrate dehydrogenase 1/2 mutational analyses and 2-hydroxyglutarate measurements in Wilms tumors.
    Rakheja D; Mitui M; Boriack RL; DeBerardinis RJ
    Pediatr Blood Cancer; 2011 Mar; 56(3):379-83. PubMed ID: 21225914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome.
    Reitman ZJ; Jin G; Karoly ED; Spasojevic I; Yang J; Kinzler KW; He Y; Bigner DD; Vogelstein B; Yan H
    Proc Natl Acad Sci U S A; 2011 Feb; 108(8):3270-5. PubMed ID: 21289278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.